Quick Take
Fulcrum Therapeutics (FULC) has filed to raise gross proceeds of $76.5 million from a U.S. IPO, according to an S-1/A registration statement.
The firm is developing treatments for genetically-defined diseases with high unmet medical need and an initial focus on rare diseases.
FULC is still in early Phase 1 safety trials for its lead candidate, so I view the IPO as more suited to long-term hold institutional investors.
Company & Technology
Cambridge, Massachusetts-based Fulcrum was founded in 2016 to develop treatments for genetically-defined diseases with high unmet medical need and